Seeking Alpha

Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in...

Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)